My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

1.760 +0.080 (+4.76%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Earnings Outlook For Editas Medicine ↗

February 27, 2024

Via Benzinga

2 Under-the-Radar Stocks With Incredible Upside Potential ↗

January 28, 2024

It's also important to consider their downsides.

Via The Motley Fool

Could Editas Medicine Become the Next CRISPR Therapeutics? ↗

January 21, 2024

Via The Motley Fool

7 Mighty Healthcare Stocks Changing the Game of Medicine ↗

January 17, 2024

Thanks to the permanent relevance of medical innovations, investors ought to consider looking at these healthcare stocks.

Via InvestorPlace

Down 88%, Could Editas Medicine Be a Good Investment Now? ↗

January 15, 2024

The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.

Via The Motley Fool

3 Stocks to Buy in the Booming Field of Gene Editing ↗

January 11, 2024

As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.

Via InvestorPlace

The Latest Analyst Ratings for Editas Medicine ↗

December 12, 2023

Via Benzinga

A Preview Of Editas Medicine's Earnings ↗

November 02, 2023

Via Benzinga

Analyst Ratings for Editas Medicine ↗

October 18, 2023

Via Benzinga

Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics ↗

January 08, 2024

These two are at very different stages of the clinical trials process.

Via The Motley Fool

Editas Just Caught a Break Thanks to Vertex Pharmaceuticals ↗

December 23, 2023

Editas isn't out of the woods yet, but it's better off than before.

Via The Motley Fool

Bull Of The Day: Crispr Therapeutics ↗

December 11, 2023

CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old...

Via Talk Markets

1 Promising Stock Down 66% That Could Skyrocket in 2024 ↗

December 05, 2023

Financial results aren't what matters most right now for this company.

Via The Motley Fool

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names ↗

November 29, 2023

As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks.

Via InvestorPlace

Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year ↗

November 22, 2023

Investors may want to strongly consider this new list of stocks to buy that could double in 2024. Check out these hidden gems.

Via InvestorPlace

The 3 Best Gene Editing Stocks on the Frontier of Medicine ↗

November 20, 2023

Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December.

Via InvestorPlace

2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street ↗

November 20, 2023

Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio?

Via The Motley Fool

3 Long-Term Growth Stocks Analysts Are Bullish On ↗

November 16, 2023

Here are three long-term growth stocks for your consideration if you’re looking to take a long position in a new name or two.

Via InvestorPlace

3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗

November 09, 2023

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

Via InvestorPlace

Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

November 03, 2023

Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.

Via Benzinga

Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday ↗

November 03, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗

October 30, 2023

This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.

Via The Motley Fool

3 Gene Editing Stocks to Generate Super-Charged Gains ↗

October 18, 2023

As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.

Via InvestorPlace

Earnings Scheduled For November 3, 2023 ↗

November 03, 2023

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023 ↗

October 18, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗

October 24, 2023

Via Benzinga

1 Risky Biotech Stock to Consider Buying, and 1 to Avoid ↗

October 18, 2023

Both are in a race against time to commercialize a medicine before cash runs out.

Via The Motley Fool

Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst ↗

October 17, 2023

Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗

October 17, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.